The initial participant has received treatment in a Phase 1 clinical trial for ZM008, an anti-LLT1 monoclonal antibody, along with LOQTORZI, a novel PD-1 inhibitor. This study aims to assess the safety and efficacy of this combination therapy. This significant milestone marks the commencement of the trial that will enroll a total of X participants to further evaluate the potential of ZM008 and LOQTORZI in treating certain conditions.